In this interview, News-Medical talks to Andre Alfaro from nanoComposix (now a Fortis Life Sciences Company) about the possibilities lateral flow assays offer in both the present and potential ...

AUSTIN, Texas and TOKYO, Sept. 9, 2025 /PRNewswire/ -- "The Lateral Flow Assays Market Size was US$ 7.51 billion in 2024, with a rise of US$ 7.50 billion in 2024, and is expected to reach US$ 15.68 ...

Adoption is tempered by notable constraints. LFAs often exhibit lower sensitivity and specificity than molecular or lab-based tests, leading to false-positive or false-negative outcomes and hindering ...

As a result of the rapidly-spreading Omicron variant, last week saw the biggest spike in Covid case numbers since records began in March 2020, with 93,045 positive tests reported in the 24 hours to ...

Scientists and public health experts built the COVID-19 pandemic response on years of experience navigating infectious disease outbreaks. Although lateral flow immunoassays have been central to ...

Report Ocean has released a market research report on the Lateral Flow Assay industry, covering 150+ countries and analyzing over 1,00000 published and forthcoming reports per year. The report, ...

Lateral flow assays, also called immunochromatographic assays, identify or measure biomolecules in intricate samples like blood, saliva, urine, or other fluids to diagnose numerous medical conditions.

The study conducted by Astute Analytica forecasts growth in revenue of the Global Lateral Flow Assays Market from US$ 9,165.7 Mn in 2021 to US$ 14,128.7 Mn by 2030. The market is registering a CAGR of ...

(MENAFN- GlobeNewsWire - Nasdaq) SNS Insider projects a 6.09% CAGR as demand for rapid, accessible testing solutions accelerates across healthcare, home diagnostics, and emerging markets. Austin, May ...

A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". The word "Markets Insider". Two crossed lines that form an 'X'. It ...

In a prospective, multicenter, adjudicator blinded clinical trial, Carl A. Deirmengian, MD, FAAOS, and colleagues conducted an alpha-defensin lateral-flow test for periprosthetic joint infection among ...